Ferring to Present Analyses for Investigational Microbiota-B

Ferring to Present Analyses for Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent C. Difficile Infection at DDW 2022.

Related Keywords

Roseville , California , United States , San Diego , Switzerland , American , Sahil Khanna , Glenn Tillotson , Lisa Ellen , Paul Feuerstadt , Ken Blount , Centers For Disease , Us Centers For Disease , American Society For Gastrointestinal Endoscopy , Brand Communications , Linkedin , Society For Surgery Of The Alimentary Tract , Ferring Pharmaceuticals , Drug Administration , Ferring Company , Yale University School Of Medicine , Rebiotix Inc , American Gastroenterological Association , Digestive Disease Week , Infection Treated , Mayo Clinic , Treatment Success , Reducing Recurrent Clostridioides , Patients With Underlying , Assistant Clinical Professor , Yale University School , New Haven , Disease Control , Fast Track , Breakthrough Therapy , American Association , Liver Diseases , American Society , Gastrointestinal Endoscopy , Alimentary Tract , Biggest Threats , Dis Clin North , Manag Care Spec , Clin Microbiol , Rev Dis , Bacteria , Disease , Infection , Medical Specialties , Merger And Acquisition , Microbiology , Spain , Pharmaceuticals , Antibiotic Resistant Bacteria , C Diff , Clostridiaceae , Clostridioides Difficile , Clostridium , Clostridium Difficile , Diarrhea , Gram Positive Bacteria ,